The University of Virginia is conducting a clinical research study for adults ages 18 and over who have relapsed and/or refractory acute myeloid leukemia. The purpose of the study is to look at the safety and efficacy of the study drug, voruciclib, alone, or in combination with venetoclax, how your body tolerates the drug or drug combination, how effective the drug(s) may be, and how the drug is taken up by your body after multiple doses over the course of the study. If you are eligible to participate in the study, you will be assigned to a dosing level and schedule (cohort) by the study doctor. The study drug administration will be broken down into 28-day cycles.
The length of time that you remain on the study will depend on how long you continue on study drug and follow-up visits. Your participation in the study can last up to 5 years. You will receive the study drug via an oral tablet.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03547115
uvacancertrials@hscmail.mcc.virginia.edu
Reimbursement: You may be reimbursed up to $175 per night for a hotel stay. You may also be reimbursed $.54 cents per mile to help cover the costs of traveling to the clinic.
No Compensation